ReviewCurrent oncology reports2014
Advances in therapy for pediatric sarcomas.
Review in Current oncology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young.Molecular cancer therapeutics · 2026Article
- A Bayesian active learning platform for scalable combination drug screens.Nature communications · 2025Article
- Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.Frontiers in oncology · 2023Review
- Review
- Advances in the Management of Pediatric Sarcomas.Current oncology reports · 2020Review
- Enhanced Antiproliferative Effect of Combined Treatment with Calcitriol and All-International journal of molecular sciences · 2020Article
- Primary undifferentiated pleomorphic cardiac sarcoma withBMJ case reports · 2018Article
- Article
- Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.The Journal of pathology · 2018Review
- Pediatric sarcomas.Oncology letters · 2018Article
- Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma.Cancer chemotherapy and pharmacology · 2016Article
- Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells.Oncotarget · 2016Article
- Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.Cancer genetics · 2016Review
- Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature.Journal of neuro-oncology · 2016Review
- Article
- Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.Scientific reports · 2015Article
- JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.Oncotarget · 2015Article
- Current management of pediatric soft tissue sarcomas.World journal of clinical pediatrics · 2015Review
- A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Cancer gene therapy · 2015Review
- In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.Journal of cancer research and clinical oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.